half-life of bicyclic peptides
therapeutic peptides
new peptide format
active bicyclic hetero peptidimer
peptide-based therapeutics
applicable new therapeutic molecule format
novel molecule format
satisfactory therapeutic options
high affinity
overall affinity
proposed project
particular target
plasma half-life
current peptide-based treatment strategies
known albumin-binding peptide
Uncontrolled FXII activity
antibody therapeutics
development of picomolar FXII inhibitors
cause
main objective
major drawbacks
severe disease hereditary angioedema
HEA
antagonist
way
local concentration
establishment
different locations
arms
potential
fold
general concept
idea
mice
step